Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry
DOI:
https://doi.org/10.2340/actadv.v102.3978Keywords:
atopic dermatitis, baricitinib, daily practice, JAK-inhibitor, PROMsAbstract
Clinical trials have shown that baricitinib, an oral selective Janus kinase 1/2 inhibitor, is effective for the treatment of moderate-to-severe atopic dermatitis. However, daily practice data are limited. Therefore, this multicentre prospective study evaluated the effectiveness and safety of 16-weeks’ treatment with baricitinib in adult patients with moderate-to-severe atopic dermatitis in daily practice. A total of 51 patients from the BioDay registry treated with baricitinib were included and evaluated at baseline and after 4, 8 and 16 weeks of treatment. Effectiveness was assessed using clinician- and patient-reported outcome measurements. Adverse events and laboratory assessments were evaluated at every visit. At week 16, the probability (95% confidence interval) of achieving Eczema Area and Severity Index ≤ 7 and numerical rating scale pruritus ≤ 4 was 29.4% (13.1–53.5) and 20.5% (8.8–40.9), respectively. No significant difference in effectiveness was found between dupilumab non-responders and responders. Twenty-two (43.2%) patients discontinued baricitinib treatment due to ineffectiveness, adverse events or both (31.4%, 9.8% and 2.0%, respectively). Most frequently reported adverse events were nausea (n = 6, 11.8%), urinary tract infection (n = 5, 9.8%) and herpes simplex infection (n = 4, 7.8%). In conclusion, baricitinib can be an effective treatment option for moderate-to-severe atopic dermatitis, including patients with non-responsiveness on dupilumab. However, effectiveness of baricitinib is heterogeneous, which is reflected by the high discontinuation rate in this difficult-to-treat cohort.
Downloads
References
Barbarot S, Auziere S, Gadkari A, Girolomoni G, Puig L, Simpson EL, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy 2018; 73: 1284-1293.
https://doi.org/10.1111/all.13401 DOI: https://doi.org/10.1111/all.13401
Zhang J, Loman L, Voorberg AN, Schuttelaar MLA. Prevalence of adult atopic dermatitis in the general population, with a focus on moderate-to-severe disease: results from the Lifelines Cohort Study. J Eur Acad Dermatol Venereol 2021; 35: e787-e790.
https://doi.org/10.1111/jdv.17471 DOI: https://doi.org/10.1111/jdv.17471
Wiedinger S, Novak N. Atopic dermatitis. Lancet 2016; 387: 1109-1122.
https://doi.org/10.1016/S0140-6736(15)00149-X DOI: https://doi.org/10.1016/S0140-6736(15)00149-X
Thaci D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 2016; 387: 40-52.
https://doi.org/10.1016/S0140-6736(15)00388-8 DOI: https://doi.org/10.1016/S0140-6736(15)00388-8
Domaingroup Allergy and Eczema and association for Atopic Dermatitis (VMCE), the Netherlands. Dupilumab (opinion) December 2020 [accessed 2022 Jun 20]. Available from https://nvdv.nl/professionals/nvdv/standpunten-en-leidraden/introductie-van-dupilumab-voor-ernstig-constitutioneel-eczeem-ce-standpunt.
Domaingroup Allergy and Eczema and assocation for Atopic Dermatitis (VMCE), the Netherlands. Baricitinib (opinion). December 2020 [accessed February 25, 2022]. Available from https://nvdv.nl/professionals/nvdv/standpunten-en-leidraden/baricitinib-standpunt.
Simpson EL, Lacour JP, Spelman L, Galimberti R, Eichenfeld LF, Bissonnette R, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol 2020; 183: 242-255.
https://doi.org/10.1111/bjd.18898 DOI: https://doi.org/10.1111/bjd.18898
Reich K, Kabashima K, Peris K, Silverberg JI, Eichenfeld LF, Bieber T, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis a randomized clinical trial. JAMA Dermatol 2020; 156: 1333-1343.
https://doi.org/10.1001/jamadermatol.2020.3260 DOI: https://doi.org/10.1001/jamadermatol.2020.3260
Guttman-Yassky E, Silvergberg JI, Nemoto O, Forman SB, Wilke A, Prescilla R, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol 201990: 913-921.
https://doi.org/10.1016/j.jaad.2018.01.018 DOI: https://doi.org/10.1016/j.jaad.2018.01.018
Wollenberg A, Nakahara T, Maari C, Peris K, Lio P, Augustin M, et al. Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomized trial. J Eur Acad Dermatol Venereol 2021; 35: 1543-1552.
https://doi.org/10.1111/jdv.17278 DOI: https://doi.org/10.1111/jdv.17278
Rogner D, Biedermann T, Lauffer F. Treatment of atopic dermatitis with baricitinib: first real-life experience. Acta Derm Venereol 2022; 102: adv00677.
https://doi.org/10.2340/actadv.v102.1088 DOI: https://doi.org/10.2340/actadv.v102.1088
Uchiyama A, Fujiwara C, Inoue Y, Motegi SI. Real-world effectiveness and safety of baricitinib in Japanese patients with atopic dermatitis: a single-center retrospective study. J Dermatol 2022; 49: 469-471.
https://doi.org/10.1111/1346-8138.16350 DOI: https://doi.org/10.1111/1346-8138.16350
Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol 2015; 172: 1353-1357.
https://doi.org/10.1111/bjd.13662 DOI: https://doi.org/10.1111/bjd.13662
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
https://doi.org/10.1111/j.1365-2230.1994.tb01167.x DOI: https://doi.org/10.1111/j.1365-2230.1994.tb01167.x
Charman CR, Venn AJ, Williams HC. The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol 2004; 140: 1513-1519.
https://doi.org/10.1001/archderm.140.12.1513 DOI: https://doi.org/10.1001/archderm.140.12.1513
Phan NQ, Blome C, Fritz F, Gerss J, Reich A, Ebata T, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol 2012; 92: 502-507.
https://doi.org/10.2340/00015555-1246 DOI: https://doi.org/10.2340/00015555-1246
Griffiths C, de Bruin-Weller M, Deleuran M, Concetta Fargnoli M, Staumont-Sallé D, Hong CH. Dupilumab in adults with moderate-to-severe atopic dermatitis and prior use of systemic non-steroidal immunosuppressants: analysis of four phase 3 trials. Dermatol Ther 2021; 11: 1357-1372.
https://doi.org/10.1007/s13555-021-00558-0 DOI: https://doi.org/10.1007/s13555-021-00558-0
Pariser DM, Simpson EL, Gadkari A, Bieber T, Margolis DJ, Brown M, et al. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT). Curr Med Res Opin 2020; 36: 367-376.
https://doi.org/10.1080/03007995.2019.1699516 DOI: https://doi.org/10.1080/03007995.2019.1699516
De Bruin-Weller M, Biedermann T, Bissonnette R, Deleuran M, Foley P, Girolomoni G, et al. Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies. Acta Derm Venereol 2021; 17: 101-102.
https://doi.org/10.2340/00015555-3751 DOI: https://doi.org/10.2340/00015555-3751
Futamara M, Leshem YA, Thomas KS, Nankervis H, Williams HC, Simpson EL. A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards. JAAD 2016; 74: 288-294.
https://doi.org/10.1016/j.jaad.2015.09.062 DOI: https://doi.org/10.1016/j.jaad.2015.09.062
Donders ART, Van der Heijden GJMG, Stijnen T, Moons KGM. Review: a gentle introduction to imputation of missing values. J Clin Epidemiol 2006; 59: 1087-1091.
https://doi.org/10.1016/j.jclinepi.2006.01.014 DOI: https://doi.org/10.1016/j.jclinepi.2006.01.014
Graham JW, Olchowski AE, Gilreath TD. How many imputations are really needed? Some practical clarifications of multiple imputation theory. Prev Sci 2007; 8: 206-213.
https://doi.org/10.1007/s11121-007-0070-9 DOI: https://doi.org/10.1007/s11121-007-0070-9
Rstudio. Available from: https://www.rstudio.com.
Robitzsch A, Grund S. (2022). miceadds: Some Additional Multiple Imputation Functions, Especially for 'mice'. R package version 3.13-1. Available from: https://CRAN.R-project.org/package=miceadds.
De Bruin-Weller MS, Serra-Baldrich E, Barbarot S, Grond S, Schuster G, Petto H, et al. Indirect treatment comparison of baricitinib versus dupilumab in adults with moderate-to- severe atopic dermatitis. Dermatol Ther 2022; 12: 1481-1491.
https://doi.org/10.1007/s13555-022-00734-w DOI: https://doi.org/10.1007/s13555-022-00734-w
Ariens LFM, Van der Schaft J, Spekhorst LS, Bakker DS, Romeijn GLE, Kouwenhoven TA. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-week results from the Dutch BioDay registry. J Am Acad Dematol 2021; 84: 1000-1009.
https://doi.org/10.1016/j.jaad.2020.08.127 DOI: https://doi.org/10.1016/j.jaad.2020.08.127
Bieber T, Thyssen JP, Reich K, Simpson EL, Katoh N, Torrelo A, et al. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. J Eur Acad Dermatol Venereol 2021; 35: 476-485.
https://doi.org/10.1111/jdv.16948 DOI: https://doi.org/10.1111/jdv.16948
Guidelli GM, Viapiana O, Luciano N, de Santis M, Boffini N, Quartuccio L, et al. Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: a real-life multicentre study. Clin Exp Rheumatol 2021; 39: 868-873.
https://doi.org/10.55563/clinexprheumatol/pudtpo DOI: https://doi.org/10.55563/clinexprheumatol/pudtpo
Iwamoto N, Sato S, Kurushima S, Michitsuij T, Nishihata S, Okamoto M, et al. Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis. Arthritis Res Ther 2021; 23: 197.
https://doi.org/10.1186/s13075-021-02582-z DOI: https://doi.org/10.1186/s13075-021-02582-z
Additional Files
Published
How to Cite
License
Copyright (c) 2022 Celeste M. Boesjes, Esmé Kamphuis, Nicolaas P.A. Zuithoff, Daphne S. Bakker, Laura Loman, Lotte S. Spekhorst, Inge Haeck, Marijke Kamsteeg, Anneke M.T. van Lynden-van Nes, Floor M.Garritsen, Klaziena Politiek, Marja Oldhoff, Marlies de Graaf, Marie L.A. Schuttelaar , Marjolein S. de Bruin-Weller
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
